• Expanded sales of Nasodine Nasal Spray in Singapore through new agreements
• Shipped retail pharmacy stocks of Nasodine to DKSH for distribution to Guardian pharmacies
• Raised $794,000 through a Share Purchase Plan during the quarter

Firebrick Pharma Limited (ASX:FRE) provided an update on its business activities for the quarter ending 31 December 2024, along with its Appendix 4C quarterly cashflow report. During the quarter, the company made significant progress in expanding the sales of Nasodine® Nasal Spray (Nasodine) in Singapore. On 31 October 2024, the company announced a Marketing Representation Agreement with Singapore-based Innorini Life Sciences, under which Innorini commenced sampling and promotion of Nasodine to doctors and other healthcare professionals in Singapore. In November 2024, the company also announced an agreement with Guardian Health & Beauty, the largest pharmacy chain in Singapore, to promote and sell Nasodine through all their retail pharmacies. To support the Guardian sales, Firebrick executed a distribution agreement with DKSH Singapore Pte Ltd to provide logistics and other services. Firebrick shipped retail pharmacy stocks of Nasodine to DKSH in December 2024 for distribution to Guardian pharmacies in January 2025. At the end of the quarter, Firebrick held cash and cash equivalents of $0.91 million, with a net cash outflow from operations of $939,000, partially offset by an inflow of $774,000 from capital raising activities, including a share purchase plan and placement to existing shareholders.

The company expects to see continued growth in online sales of Nasodine in the future, as well as significant additional sales of Nasodine to healthcare professionals and through retail pharmacy in Singapore following the retail and healthcare professional launches.